Once-daily maraviroc in combination with ritonavir-boosted atazanavir in treatment-naive patients infected with CCR5-tropic HIV-1 (study A4001078): 96-week results

被引：0

作者：

Mills, A. ^{[1
]}

Mildvan, D. ^{[2
]}

Podzamczer, D. ^{[3
]}

Faetkenheuer, G. ^{[4
]}

Leal, M. ^{[5
]}

Than, S. ^{[6
]}

Valluri, S. R. ^{[9
]}

Craig, C. ^{[10
]}

Vourvahis, M. ^{[9
]}

Heera, J. ^{[6
]}

Valdez, H. ^{[9
]}

Brown, T. ^{[7
]}

Rinehart, A. ^{[8
]}

Portsmouth, S. ^{[9
]}

机构：

[1] Anthony Mills MD Inc, Los Angeles, CA USA

[2] Beth Israel Deaconess Med Ctr, Div Infect Dis, New York, NY 10003 USA

[3] Hosp Univ Bellvitge, HIV Unit, Infect Dis Serv, Barcelona, Spain

[4] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany

[5] Virgen del Rocio Univ Hosp, Infect Dis Serv, Seville, Spain

[6] Pfizer Inc, Groton, CT 06340 USA

[7] Johns Hopkins Univ, Div Endocrinol & Metab, Baltimore, MD USA

[8] ViiV Healthcare, Res Triangle Pk, NC USA

[9] Pfizer Inc, New York, NY USA

[10] Pfizer Inc, Sandwich, Kent, England

来源：

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：52 / 53

页数：2